Skip to content

Study · Systematic review · 2009

9 results

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.

Monami M, Marchionni N, Mannucci E

European journal of endocrinology24 Mar 2009Cited by 98 (Europe PMC)

PMID19318378 (opens in a new tab)DOI10.1530/eje-09-0101 (opens in a new tab)PepBankPUB-19318378
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    Available data suggest that the efficacy of once-daily liraglutide is comparable with that of exenatide twice daily in adults with type 2 diabetes.

    In plain wordsIn adults with type 2 diabetes, once-daily liraglutide worked about as well as exenatide twice daily.

    Peptide
    Liraglutide
    Outcome
    No significant changeEfficacy of liraglutide versus exenatide twice daily
    Study

    n: not reported in source

    Comparator
    Exenatide twice daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Available data suggest that the efficacy and tolerability of the novel agent, liraglutide, which is adequate for once-a-day administration, are comparable with those of exenatide bis in die.
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.
  2. 02HumanSystematic reviewSafety outcome

    Available data suggest that the tolerability of once-daily liraglutide is comparable with that of exenatide twice daily in adults with type 2 diabetes.

    In plain wordsIn adults with type 2 diabetes, once-daily liraglutide was about as well tolerated as exenatide twice daily.

    Peptide
    Liraglutide
    Outcome
    No significant changeTolerability of liraglutide versus exenatide twice daily
    Study

    n: not reported in source

    Comparator
    Exenatide twice daily
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Available data suggest that the efficacy and tolerability of the novel agent, liraglutide, which is adequate for once-a-day administration, are comparable with those of exenatide bis in die.
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (exenatide and liraglutide) improved HbA1c versus placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group, including liraglutide, lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c difference
    −1%
    GLP-1 receptor agonists vs placebo

    Source sentences

    Summary
    GLP-1 receptor agonists determine a significant improvement of HbA1c in comparison with placebo (-1.0 (-1.1, -0.8), P<0.001)
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Pooled GLP-1 receptor agonists (exenatide and liraglutide) carried a low risk of hypoglycaemia in adults with type 2 diabetes.

    In plain wordsGLP-1 drugs as a group, including liraglutide, carried a low risk of low blood sugar in adults with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    with a low risk of hypoglycaemia.
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes, the meta-analysis found no evidence of increased cardiovascular risk with GLP-1 receptor agonists (exenatide and liraglutide).

    In plain wordsThe pooled trials showed no sign of higher heart and blood vessel risk with GLP-1 drugs, including liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeCardiovascular risk
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    There is no evidence of increased cardiovascular risk with the use of GLP-1 receptor agonists.
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    Pooled GLP-1 receptor agonists (exenatide and liraglutide) induced weight loss in adults with type 2 diabetes.

    In plain wordsGLP-1 drugs as a group, including liraglutide, led to weight loss in adults with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP-1 receptor agonists, which induce weight loss
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Pooled GLP-1 receptor agonists (exenatide and liraglutide) were associated with gastrointestinal side effects in adults with type 2 diabetes.

    In plain wordsGLP-1 drugs as a group, including liraglutide, were linked to stomach and gut side effects.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal side effects
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    GLP-1 receptor agonists, which induce weight loss, are associated with gastrointestinal side effects.
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    Pooled GLP-1 receptor agonists (exenatide and liraglutide) were effective in reducing postprandial glucose in adults with type 2 diabetes.

    In plain wordsGLP-1 drugs as a group, including liraglutide, lowered blood sugar after meals in adults with type 2 diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    GLP-1 receptor agonists are effective in reducing HbA1c and postprandial glucose.
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes failing sulphonylureas or metformin, pooled GLP-1 receptor agonists (exenatide and liraglutide) were similarly effective as insulin.

    In plain wordsIn adults with type 2 diabetes not controlled by other drugs, GLP-1 drugs, including liraglutide, worked about as well as insulin.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlycaemic efficacy versus insulin
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In patients failing to sulphonylureas and/or metformin, GLP-1 receptor agonists are similarly effective as insulin.
    1 context sentence
    Summary · context
    All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, body mass index, hypoglycaemia and other adverse events.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.